Jiangsu Jibeier Pharmaceutical (688566) investor relations material

Executive summary

• Revenue for H1 2026 reached ¥489.55 million, up 7.61% year-over-year, but net profit attributable to shareholders dropped 33.54% to ¥99.24 million due to a sharp decline in non-operating income.

• Core products maintained leading market positions, and R&D for innovative drugs advanced, with key projects entering late-stage clinical or registration phases.

• The company continued to invest in production capacity and R&D infrastructure, including new plant and high-end formulation center projects.

• A cash dividend of ¥2.60 per 10 shares (pre-tax) was proposed, totaling ¥52.29 million.

Financial highlights

• Operating income: ¥489.55 million (+7.61% YoY); net profit: ¥99.24 million (-33.54% YoY).

• Operating cash flow: ¥133.11 million (-15.18% YoY).

• Basic and diluted EPS: ¥0.50 (-33.33% YoY); ROE: 4.00% (-2.44pp YoY).

• R&D investment: ¥27.68 million, 5.65% of revenue.

• Total assets: ¥2.78 billion (+2.40% from year-end 2025); net assets: ¥2.52 billion (+3.51%).

Outlook and guidance

• The company expects continued growth in the pharmaceutical sector, driven by aging demographics and healthcare demand.

• Key innovative drugs (e.g., JJH201501, JJH201601) are progressing toward commercialization, with anticipated regulatory submissions and late-stage trials.

• Ongoing investment in R&D and production capacity is expected to support long-term growth.